Actinogen reports an active six months with accelerated development of the Xanamem molecule

February 24, 2025 05:30 PM AEDT | By Team Kalkine Media

Actinogen reports an active six months with accelerated development of the Xanamem molecule — Image source: shutterstock

Clinical Progress with Xanamem

Actinogen Medical has been advancing the development of Xanamem, its lead molecule designed to address cognitive and mood disorders. Research activities have been a primary driver of expenditures, with a significant portion allocated to clinical trials. The company’s latest financial report indicates a reduction in net loss, reflecting an emphasis on accelerating research while maintaining financial discipline.

Advancements in Clinical Trials

The development of Xanamem has seen meaningful progress, with multiple trials contributing to its evaluation. The XanaMIA Phase 2b/3 trial is actively investigating its effectiveness in Alzheimer’s disease, while the completion of the XanaCIDD Phase 2a trial for major depressive disorder has delivered encouraging findings. Data from this study support the concept that regulating cortisol may play a critical role in addressing depressive symptoms. These findings have paved the way for further research, with preparations underway for an additional phase of study in this area.

Recognition and Scientific Contributions

The company has also achieved key scientific milestones beyond clinical trials. The World Health Organization has assigned the international nonproprietary name "emestedastat" to Xanamem, marking an important step in its development. Additionally, Actinogen Medical has contributed to the scientific community through the publication of trial findings in the peer-reviewed journal "Clinical Pharmacology in Drug Development." This publication provides insights into the molecule’s clinical evaluation and mechanisms of action.

Financial Developments and Research Incentives

Actinogen Medical has strengthened its financial foundation through a research and development rebate received in recent months. This funding supports ongoing studies and extends the company’s operational timeline, enabling sustained progress in research initiatives. The financial commitment to Xanamem’s development underscores the company’s strategic direction in neurological drug development.

Market Performance and Strategic Focus

Recent market activity reflected a decrease in Actinogen Medical’s share price, aligning with broader market dynamics. Despite this movement, the company continues to prioritize clinical advancements and regulatory engagement. With a focus on securing approvals and progressing research, Actinogen Medical remains active in the pursuit of treatments that address significant unmet needs in neurology.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.